FrancophonIA/ELRC3.0 huggingface dataset:
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Matever.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: What is Matever?
Estonian: Mis on Matever?
English: Matever tablets are swallowed with liquid.
Estonian: Mateveri tabletid neelatakse koos vedelikuga.
English: The Committee recommended that Matever be given marketing authorisation.
Estonian: Komitee soovitas anda ravimi müügiloa.
English: Matever is a medicine that contains the active substance levetiracetam.
Estonian: Matever on ravim, mis sisaldab toimeainena levetiratsetaami.
English: Because Matever is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Matever on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Matever is a ‘generic medicine'.
Estonian: Matever on geneeriline ravim.
English: Why has Matever been approved?
Estonian: Miks Matever heaks kiideti?
English: What are the benefits and risks of Matever?
Estonian: Milles seisneb Mateveri kasulikkus ja mis riskid ravimiga kaasnevad?
English: • myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in patients from 12
Estonian: • müokloonilisi episoode (lühiajalised šokitaolised lihaste või lihasrühmade tõmblused) vähemalt 12
English: Matever can be used on its own in patients from 16 years of age with newly diagnosed epilepsy, to treat partial-onset seizures (fits) with or without secondary generalisation.
Estonian: Mateveri tohib kasutada ainsa ravimina vähemalt 16-aastastel patsientidel, kellel on äsja diagnoositud epilepsia, et ravida sekundaarse generalisatsiooniga või sekundaarse generalisatsioonita partsiaalseid episoode.
English: This means that Matever is similar to a ‘reference medicine' already authorised in the European Union (EU) called Keppra.
Estonian: See tähendab, et Matever on sarnane võrdlusravimiga Keppra, millel juba on Euroopa Liidus müügiluba.
English: The CHMP concluded that, in accordance with EU requirements, Matever has been shown to have comparable quality and to be bioequivalent to Keppra.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Matever võrdväärne kvaliteet ja bioekvivalentsus ravimiga Keppra.
English: Matever can also be used as an add-on to other anti-epileptic medicines to treat:
Estonian: Mateveri tohib kasutada ka teiste epilepsiaravimite lisaravimina, et ravida
English: Because Matever is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Keppra.
Estonian: Et Matever on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati Mateveri bioekvivalentsust võrdlusravimiga Keppra.
English: In patients aged between six months and 17 years weighing less than 50 kg, the starting dose is 10 mg per kilogram body weight twice a day, which can be increased up to 30 mg/kg twice a day.
Estonian: Vähemalt 6-kuulistel kuni 17-aastastel patsientidel kehamassiga alla 50 kg on algannus 10 mg kehamassi kg kohta kaks korda ööpäevas, seda annust tohib suurendada annuseni 30 mg/kg, mida manustatakse kaks korda ööpäevas.
English: • partial-onset seizures with or without generalisation in patients from one month of age;
Estonian: • sekundaarse generalisatsiooniga või sekundaarse generalisatsioonita partsiaalseid episoode vähemalt 1-kuulistel patsientidel;
English: When Matever is added to another anti-epileptic treatment, the starting dose in patients over 12 years weighing more than 50 kg is 500 mg twice a day.
Estonian: Mateveri lisamisel teisele epilepsiaravimile vähemalt 12-aastastel patsientidel kehamassiga üle 50 kg on algannus 500 mg kaks korda ööpäevas.
English: The daily dose can be increased up to 1500 mg twice a day.
Estonian: Ööpäevast annust tohib suurendada 1500 mg-ni kaks korda ööpäevas.
English: How is Matever used?
Estonian: Kuidas Mateveri kasutatakse?
English: The active substance in Matever, levetiracetam, is an anti-epileptic medicine.
Estonian: Mateveri toimeaine levetiratsetaam on epilepsiaravim.
English: How has Matever been studied?
Estonian: Kuidas Mateveri uuriti?
English: What is Matever used for?
Estonian: Milleks Mateveri kasutatakse?
English: When Matever is used on its own, the starting dose is 250 mg twice a day, increasing two weeks later to 500 mg twice a day.
Estonian: Mateveri kasutamisel ainsa ravimina on algannus 250 mg kaks korda ööpäevas, seda suurendatakse kahe nädala pärast 500 mg-ni kaks korda ööpäevas.
English: Matever can be given as an infusion using the same doses at the same frequency when using the tablets or the oral solution is not possible.
Estonian: Kui tablette või suukaudset lahust ei saa kasutada, tohib Mateveri manustada infusiooni teel, kasutades sama sagedusega samu annuseid.
English: How does Matever work?
Estonian: Kuidas Matever toimib?
English: The dose can be further increased at two-week intervals according to the patient's response, to a maximum dose of 1500 mg twice a day.
Estonian: Olenevalt patsiendi ravivastusest tohib annust 2nädalase intervalliga suurendada kuni maksimaalse annuseni 1500 mg kaks korda ööpäevas.
English: This summary was last updated on 16 April 2009.
Estonian: Kokkuvõtte viimane uuendus: 16. aprill 2009.
English: Swelling after the first vaccination normally resolves within 30 days, and may last at least 35 days following the second vaccination.
Estonian: Esimese vaktsineerimise järel tekkinud paistetus taandub tavaliselt 30 päeva jooksul ning võib püsida vähemalt 35 päeva pärast teist vaktsineerimist.
English: If pain persists for more than 12 hours after examination, seek medical advice again.
Estonian: Kui valu püsib pärast läbivaatust üle 12 tunni, peab arsti poole pöörduma uuesti.
English: The hen can continue to pass on immunity to her chicks for almost a year after the end of vaccination.
Estonian: Kana jätkab immuunsuse edasi andmist tibudele ligikaudu aasta pärast vaktsineerimise lõppu.
English: Netvax is a vaccine.
Estonian: Netvax on vaktsiin.
English: Accidental injection of Netvax can cause severe pain and swelling, particularly if it is accidentally injected into a joint or finger.
Estonian: Juhuslik enesesüstimine võib põhjustada tugevat valu ja paistetust, eriti kui juhuslikult süstitakse liigesesse või sõrme.
English: The vaccine protected the chicks during the early period of life, when they are at greatest risk of the disease.
Estonian: Vaktsiin kaitses tibusid varasel eluperioodil, kui haigestumisrisk on kõige suurem.
English: This second dose should be given at least six weeks before the hen will start to lay eggs.
Estonian: Teine annus tuleb manustada vähemalt 6 nädalat enne munemise algust.
English: The vaccination schedule consists of two doses: the first dose is given at 10 to 14 weeks of age, and then a second dose is given four to 10 weeks after the first.
Estonian: Vaktsineerimisskeem koosneb kahest annusest: esimene annus manustatakse 10…14 nädala vanuses ja teine annus manustatakse 4…10 nädalat pärast esimest annust.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Netvax to Intervet International B.V. on 16 April 2009.
Estonian: Euroopa Komisjon andis Netvaxi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Intervet International B.V.
English: The CVMP recommended that Netvax should be given a marketing authorisation.
Estonian: Veterinaarravimite komitee soovitas anda Netvaxile müügiloa.
English: The vaccine also contains an ‘adjuvant' (mineral oil) to stimulate a better response.
Estonian: Vaktsiin sisaldab parema ravivastuse saamiseks ka adjuvanti (mineraalõli).
English: What is the risk associated with Netvax?
Estonian: Mis riskid Netvaxiga kaasnevad?
English: What is Netvax?
Estonian: Mis on Netvax?
English: The studies compared chickens vaccinated with Netvax with birds that did not receive the vaccine.
Estonian: Uuringutes võrreldi Netvaxiga vaktsineeritud kanu nendega, kes vaktsiini ei saanud.
English: Other information about Netvax:
Estonian: Muu teave Netvaxi kohta
English: Birds with the disease fail to thrive.
Estonian: Selle haigusega linnud ei kasva.
English: The antibodies are transferred from the chicken to the chicks via the eggs.
Estonian: Antikehad kanduvad kanadelt tibudele munade kaudu.
English: Necrotising enteritis is a disease that causes damage to the gut.
Estonian: Nekrootiline enteriit on soolestikku kahjustav haigus.
English: If accidental injection happens, seek prompt medical advice and show the package leaflet to the doctor.
Estonian: Juhusliku enesesüstimise korral tuleb pöörduda kohe arsti poole ja näidata ravimi pakendi infolehte.
English: The effectiveness of Netvax has been studied in several trials under laboratory and field conditions in chickens and their chicks.
Estonian: Netvaxi efektiivsust on uuritud mitmes kanade ja tibude labori- ning väliuuringus.
English: The vaccine was well tolerated by the chickens, with no effect on the production of eggs or chicks.
Estonian: Kanad talusid vaktsiini hästi, see ei mõjutanud nende tootlikkust munade ega tibude osas.
English: Why has Netvax been approved?
Estonian: Miks Netvax heaks kiideti?
English: The main measure of effectiveness was the production of protective antibodies against C. perfringens type A in the chickens' blood and in their eggs.
Estonian: Efektiivsuse põhinäitaja oli kaitsvate antikehade teke bakteri C. perfringensi A-tüübi vastu kanade veres ja munades.
English: Vaccination causes swelling at the site of injection.
Estonian: Vaktsineerimine põhjustab paistetust süstekohas.
English: The studies also looked at death rates in the chicks hatched by vaccinated hens, and at the incidence and the severity of lesions caused by necrotic enteritis in the gut after the chicks were deliberately infected with the bacterium at three weeks of age.
Estonian: Uuringutes vaadeldi ka vaktsineeritud kanade munadest koorunud tibude suremust ning nekrootilise enteriidi põhjustatud soolestikukahjustuste esinemissagedust ja raskust tibudel, kes kolme nädala vanusena nakatati selle bakteriga sihilikult.
English: In chicks hatched from vaccinated hens, the vaccine reduced the number of deaths, and the incidence and the severity of lesions caused by necrotic enteritis.
Estonian: Vaktsineeritud kanade munadest koorunud tibudel vähendas vaktsiin suremust ning nekrootilise enteriidi põhjustatud kahjustuste esinemissagedust ja raskust.
English: The studies showed that the vaccine is effective in stimulating the production of antibodies in chickens and in their eggs.
Estonian: Uuringute andmeil on vaktsiin efektiivne antikehade tekke soodustamisel kanadel ja munades.
English: Netvax is used to reduce the number of deaths, and the incidence and severity of the disease.
Estonian: Netvaxi kasutatakse kanade suremuse ning haiguse esinemissageduse ja raskuse vähendamiseks.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Netvax exceed the risks for the active immunisation of chickens, to provide passive immunisation against necrotic enteritis to their progeny, during the laying period, to reduce mortality and the incidence and severity of lesions caused by C. perfringens type A-induced necrotic enteritis.
Estonian: Veterinaarravimite komitee otsustas, et Netvaxi kasulikkus kasutamisel kanade aktiivseks immuniseerimiseks eesmärgiga tagada nende järglaste passiivne immuniseerimine nekrootilise enteriidi vastu munemisperioodil ja vähendada bakteri C. perfringens A-tüübi tekitatud nekrootilise enteriidi põhjustatud suremust, kahjustuste esinemissagedust ja raskust, on suurem kui sellega kaasnevad riskid.
English: What benefit has Netvax shown during the studies?
Estonian: Milles seisneb uuringute põhjal Netvaxi kasulikkus?
English: Netvax is used to vaccinate chickens against necrotic enteritis caused by C. perfringens type A, so that they pass their immunity against the disease on to their chicks.
Estonian: Netvaxi kasutatakse kanade vaktsineerimiseks bakteri C. perfringens A-tüübi põhjustatud nekrootilise enteriidi vastu, et nad annaksid haigusevastase immuunsuse edasi tibudele.
English: What is Netvax used for?
Estonian: Milleks Netvaxi kasutatakse?
English: These antibodies help the chicks to fight necrotic enteritis caused by C. perfringens type A if they are exposed to the bacterium after they have hatched.
Estonian: Antikehad aitavad tibudel võidelda bakteri C. perfringens A-tüübi põhjustatud nekrootilise enteriidiga, kui tibud puutuvad pärast koorumist selle bakteriga kokku.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) NETVAX EPAR summary for the public
Estonian: NETVAX Kokkuvõte üldsusele
English: Netvax is a vaccine that contains a toxoid (a weakened toxin) from the bacterium Clostridium perfringens (C. perfringens) type A. The vaccine is an emulsion (a mixture of oil- and water-based liquids) for injection.
Estonian: Netvax on vaktsiin, mis sisaldab bakteri Clostridium perfringens (C. perfringens) A-tüübi toksoidi (nõrgestatud toksiini).
English: How does Netvax work?
Estonian: Kuidas Netvax toimib?
English: Netvax contains one type of the toxoid from C. perfringens called the alpha toxoid.
Estonian: Netvax sisaldab bakteri C. perfringens toksoidi teatud tüüpi, alfatoksoidi.
English: How has Netvax been studied?
Estonian: Kuidas Netvaxi uuriti?
English: Netvax is given by injection into the breast muscle.
Estonian: Ravimit manustatakse lihasesisese süstena.
English: Netvax contains small amounts of a toxoid from C. perfringens type A. When it is given to a chicken, its immune system recognises the toxoid as ‘foreign' and makes antibodies against it.
Estonian: Kui kanale manustatakse vaktsiini, peab immuunsüsteem toksoidi võõraks ja tekitab selle vastu antikehi.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Tecfidera on 30 January 2014.
Estonian: Euroopa Komisjon andis Tecfidera müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 30. Jaanuaril 2014.
English: A risk management plan has been developed to ensure that Tecfidera is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Tecfidera võimalikult ohutu kasutamine.
English: These side effects tend to start early during treatment, usually in the first month, and may continue intermittently throughout treatment.
Estonian: Need kõrvalnähud esinevad tavaliselt ravi jooksul üsna vara, esimese kuu jooksul, ja võivad jätkuda aegajalt ravi jooksul.
English: In addition, a number of studies with Tecfidera are planned or underway to provide further long-term safety data and to monitor the medicine.
Estonian: Veel on kavandatud või käimas mitmed uuringud Tecfideraga, et anda edasisi pikaajalisi ohutusandmeid ja jälgida ravimit.
English: Tecfidera is available as oral capsules (120 and 240 mg) to be taken with food.
Estonian: Tecfiderat turustatakse suukaudsete kapslitena (120 ja 240 mg), mis võetakse sisse koos toiduga.
English: What measures are being taken to ensure the safe and effective use of Tecfidera?
Estonian: Mis meetmed võetakse, et tagada Tecfidera ohutu ja efektiivne kasutamine?
English: The full EPAR for Tecfidera can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Tecfidera kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Tecfidera
Estonian: Muu teave Tecfidera kohta
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore concluded that Tecfidera's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas seetõttu, et Tecfidera kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Tecfidera dimethyl fumarate
Estonian: Tecfidera dimetüülfumaraat
English: What is Tecfidera and what is it used for?
Estonian: Mis on Tecfidera ja milleks seda kasutatakse?
English: Tecfidera is a medicine that contains the active substance dimethyl fumarate.
Estonian: Tecfidera on ravim, mis sisaldab toimeainena dimetüülfumaraati.
English: This is a summary of the European public assessment report (EPAR) for Tecfidera.
Estonian: See on ravimi Tecfidera Euroopa avaliku hindamisaruande kokkuvõte.
English: In a second main study involving 1,417 patients, patients were given Tecfidera, placebo or another medicine, glatiramer acetate.
Estonian: Teises põhiuuringus, milles osales 1417 patsienti, anti patsientidele Tecfiderat, platseebot või teist ravimit - glatirameeratsetaati.
English: The number of relapses per patient per year for glatiramer acetate was 0.3.
Estonian: Relapside arv patsiendi kohta aastas oli glatirameeratsetaadi manustamisel 0,3.
English: Why is Tecfidera approved?
Estonian: Miks Tecfidera heaks kiideti?
English: The dose is 120 mg twice a day for the first seven days, after which it is increased to 240 mg twice a day.
Estonian: Annus on 120 mg kaks korda ööpäevas esimese seitsme päeva jooksul.
English: This study showed Tecfidera to be more effective than placebo in reducing the number of relapses over the course of two years: the number of relapses per patient per year was around 0.2 with Tecfidera compared with 0.4 with placebo.
Estonian: See uuring näitas, et Tecfidera on relapside arvu vähendamisel kahe aasta jooksul platseebost efektiivsem: relapside arv patsiendi kohta aastas oli umbes 0,2 Tecfidera manustamisel võrreldes 0,4ga platseebo puhul.
English: The active substance, dimethyl fumarate, is thought to work by activating a protein called ‘Nrf2' that regulates certain ‘antioxidant' genes involved in protecting cells from damage.
Estonian: Arvatakse, et toimeaine dimetüülfumaraat aktiveerib valku Nrf2, mis reguleerib teatud antioksüdantseid geene, mis osalevad rakkude kaitsmisel kahjustuste eest.
English: It is not intended to provide practical advice on how to use Tecfidera.
Estonian: Hindamisaruandes ei anta Tecfidera kasutamise praktilisi nõuandeid.
English: The dose may be reduced temporarily in patients experiencing side effects of flushing and gastrointestinal problems.
Estonian: Annust tohib ajutiselt vähendada patsientidel, kellel esinevad kõrvalnähtudena õhetus ja gastrointestinaalsed probleemid.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Tecfidera, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Tecfidera omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: The most common side effects with Tecfidera (which may affect more than 1 in 10 people) are flushing (reddening of skin) and gastrointestinal problems (such as diarrhoea, nausea, and pain in the abdominal area).
Estonian: Tecfidera kõige sagedamad kõrvalnähud (võivad esineda kuni 1 patsiendil 10st) on õhetus (nahapunetus) ja gastrointestinaalsed probleemid (kõhulahtisus, iiveldus ja valu kõhupiirkonnas).
English: In a main study involving 1,234 patients, the proportion of patients who experienced a relapse over the course of two years was significantly lower with Tecfidera treatment than with placebo (a dummy treatment): 27% versus 46%.
Estonian: Põhiuuringus, milles osales 1234 patsienti, oli patsientide osakaal, kellel esines relaps kahe aasta jooksul, oluliselt väiksem ravi korral Tecfideraga (27%) kui platseeboga (näiv ravim) (46%).
English: Dimethyl fumarate, has been shown in studies to reduce the inflammation and modulate the activity of the immune system.
Estonian: Uuringutes on näidatud, et dimetüülfumaraat vähendab põletikku ja moduleerib immuunsüsteemi aktiivsust.
English: What are the risks associated with Tecfidera?
Estonian: Mis riskid Tecfideraga kaasnevad?
English: For more information about treatment with Tecfidera, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Tecfideraga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: For practical information about using Tecfidera, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Tecfidera kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For the full list of all side effects reported with Tecfidera, see the package leaflet.
Estonian: Tecfidera kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: It is used specifically in adults with a type of MS known as relapsing-remitting MS, where the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions).
Estonian: Tecfiderat kasutatakse ägenemiste ja remissioonidega kulgeva hulgikoldekõvastumuse tüübi puhul, kui patsiendil esinevad sümptomite ägenemised (relapsid), mis vahelduvad taastumisperioodidega (remissioonidega).
English: In MS, the body's immune system malfunctions and attacks parts of the central nervous system (the brain and spinal cord), causing the inflammation that damages the nerve sheaths.
Estonian: Hulgikoldekõvastumuse korral on organismi immuunsüsteemi talitlus häiritud, mistõttu see ründab kesknärvisüsteemi teatud osi (pea- ja seljaaju), põhjustades põletikku, mis kahjustab närvirakke ümbritsevat kaitsekesta.
English: It is used to treat multiple sclerosis (MS), a disease in which inflammation destroys the protective sheath around the nerves.
Estonian: Hulgikoldekõvastumus on haigus, mille korral hävitab põletik närve ümbritseva kaitsekesta.
English: How is Tecfidera used?
Estonian: Kuidas Tecfiderat kasutatakse?
English: Tecfidera has been shown to be effective in reducing the number of relapses in patients with relapsingremitting MS and in reducing the number of patients who have relapses during treatment.
Estonian: On näidatud, et Tecfidera on efektiivne relapside arvu vähendamisel ägenemiste ja remissioonidega kulgeva hulgikoldekõvastumusega patsientidel ja patsientide arvu vähendamisel, kellel ravi ajal esinevad relapsid.
English: How does Tecfidera work?
Estonian: Kuidas Tecfidera toimib?
English: The main risks identified with Tecfidera are considered to be manageable and include flushing and gastrointestinal problems (the most common side effects), as well as reduced levels of white blood cells and protein in the urine.
Estonian: Nende hulka kuuluvad õhetus ja gastrointestinaalsed probleemid (kõige sagedamad kõrvalnähud), samuti valgete vererakkude arvu vähenemine ning valk uriinis.
English: Tecfidera has been shown to reduce the number of relapses in patients with relapsing-remitting MS and to reduce the number of patients who have them.
Estonian: On näidatud, et Tecfidera vähendab relapside arvu ägenemiste ja remissioonidega kulgeva hulgikoldekõvastumusega patsientidel ja vähendab ägenemiste ja remissioonidega patsientide arvu.
English: What benefits of Tecfidera have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Tecfidera kasulikkus?
English: Tecfidera can only be obtained with a prescription and treatment should be started under the supervision of a doctor experienced in treating MS.
Estonian: Ravi peab algama arsti järelevalve all, kes on kogenud hulgikoldekõvastumuse ravis.
English: The conclusions of the study are accepted.
Estonian: Uuringu järeldused on vastuvõetavad.
English: Those data can be summarised as follows:
Estonian: Nimetatud andmed võib kokku võtta järgmiselt.
English: Elimination half-life was estimated to be 13.76 + 6.42 hours.
Estonian: Eliminatsiooni poolväärtusaeg on hinnanguliselt 13,76 ±6,42 tundi.